ST. PETERSBURG, USA
St. Petersburg in the primary softgel development and manufacturing facility in North America. The site has the capability to develop lipid formulations in a dedicated pilot plant which supports rapid transition from laboratory scale to clinical supply. Liquid in bottle, as well as Liquid fill Hard shell capabilities at the facility provide diversification and offerings that increase the speed to clinic. Within the Catalent network, we offer a broad range of integrated formulation and analytical services to solve your most difficult development and manufacturing challenges. Our analytical laboratory provides a full service offering from development of analytical methods to routine QC testing, supporting commercial and development stability studies. With capacity to generate over 18 billion softgels per year and servicing over 100 markets globally, the St. Petersburg site can handle any Over the Counter (OTC), Prescription (Rx), Medical Device, Controlled Substance, or Dietary Supplement manufacturing needs. The facility also contains a segregated hormone manufacturing area that meets current regulatory requirements. In addition to the manufacturing of traditional animal based gelatin softgels, St. Petersburg site manufactures products in non-gelatin based OptiShell® and Vegicaps®to expand the range of molecules that can be encapsulated.
Size: 500,000 ft2
ADDRESS
2725 Scherer Drive North,
St. Petersburg, FL 33716
PHONE
+1 727 803-2100
FAX
+1 727 803-1639
CAPABILITIES:
- Rx and OTC Softgel development and manufacturing
- Formulation Development and Manufacturing services for:
FEATURED TECHNOLOGIES:
ACCREDITATION
- EMA/MHRA Approved
- FDA Approved
- ANVISA
- PMDA
- CFDA (China)
- MOH (Saudi Arabia, Turkey)
- MFDS
SALES INQUIRIES
Reach out to one of our experts to discuss any of our offerings or a specific solution for your project challenges.
CAREERS
We recognize talent is our most important asset. To explore a career with Catalent, visit our Careers Section to submit your resume.